Söndag 30 Augusti | 15:15:00 Europe / Stockholm
Est. tid*
2027-05-28 08:30 Bokslutskommuniké 2027
2027-02-26 08:30 Kvartalsrapport 2027-Q3
2026-11-26 08:30 Kvartalsrapport 2027-Q2
2026-09-10 N/A X-dag ordinarie utdelning QCORE 0.00 SEK
2026-09-09 N/A Årsstämma
2026-09-09 08:30 Kvartalsrapport 2027-Q1
2026-05-28 - Bokslutskommuniké 2026
2026-02-26 - Kvartalsrapport 2026-Q3
2025-11-27 - Kvartalsrapport 2026-Q2
2025-09-24 - Kvartalsrapport 2026-Q1
2025-09-11 - X-dag ordinarie utdelning QCORE 0.00 SEK
2025-09-10 - Årsstämma
2025-07-31 - Extra Bolagsstämma 2026
2025-06-18 - Bokslutskommuniké 2025
2025-03-26 - Kvartalsrapport 2025-Q3
2024-11-28 - Kvartalsrapport 2025-Q2
2024-09-11 - X-dag ordinarie utdelning QCORE 0.00 SEK
2024-09-10 - Årsstämma
2024-08-29 - Kvartalsrapport 2025-Q1
2024-05-30 - Bokslutskommuniké 2024
2024-02-28 - Kvartalsrapport 2024-Q3
2023-11-28 - Kvartalsrapport 2024-Q2
2023-09-08 - X-dag ordinarie utdelning QCORE 0.00 SEK
2023-09-07 - Årsstämma
2023-08-30 - Kvartalsrapport 2024-Q1
2023-05-30 - Bokslutskommuniké 2023
2023-02-28 - Kvartalsrapport 2023-Q3
2022-11-28 - Kvartalsrapport 2023-Q2
2022-09-08 - X-dag ordinarie utdelning QCORE 0.00 SEK
2022-09-07 - Årsstämma
2022-08-30 - Kvartalsrapport 2023-Q1
2022-06-08 - Bokslutskommuniké 2022
2022-02-28 - Kvartalsrapport 2022-Q3
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlucore utvecklar AI‑baserad programvara som används inom sjukvårdssektorn. Genom bolagets lösningar för precisionsmedicin omvandlas genetisk data till beslutsunderlag, för att skapa förutsättningar för rätt behandling till patienter. Bolagets första diagnostiska test – för blodcancer hos barn – är godkänt och CE-märkt. Bolaget har även tester för lungcancer under utveckling, samt utvecklar analysprogrammet Qlucore Omics Explorer.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Qlucore Signs Agreement with BioTuring Inc

2026-08-26 14:00:00

Nasdaq First North-listed Qlucore, a leading provider of software for data analysis and precision diagnostics, today announced that it has entered into a reseller agreement with BioTuring, a pioneering bioinformatics software company based in San Diego, USA. Through this collaboration, Qlucore will distribute BioTuring’s software solutions across Europe.

BioTuring is a bioinformatics company pioneering computational platforms that reveal the complexity of biology to improve human health. Its integrated solutions, including SpatialX for spatial multi-omics analysis, BBrowserX Pro for single-cell RNA sequencing, and Talk2Data, the world's largest curated public study database, provide GPU-accelerated technologies that enable researchers and biopharmaceutical companies to explore biological data at unprecedented speed and depth, driving breakthroughs in oncology, immunology, neuroscience and beyond.

BioTuring's products will be available to Qlucore customers alongside Qlucore Omics Explorer, giving European researchers access to a wider set of tools for analyzing complex biological data through a single point of contact.

Under the agreement, Qlucore will market, sell, and provide first-line support for BioTuring’s solutions to customers across Europe. The target customer base includes universities, biotechnology companies, and pharmaceutical organizations — segments where Qlucore has established strong relationships and domain expertise.

“What scientists can learn from a single cell, or from the spatial context around it, has changed rapidly in the past few years. This agreement with Qlucore helps more researchers in Europe engage with that work,” said Son Pham, CEO of BioTuring.

“The addition of BioTuring’s innovative and powerful software solutions enhances our portfolio and strengthens our position in the European market,” said Carl-Johan Ivarsson, CEO of Qlucore. “By combining BioTuring’s technology with Qlucore’s deep customer insight and long-standing relationships, we can better support researchers and organizations in accelerating discovery and innovation—turning complex data into clear, actionable insights.”